Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Tumor Lysate Pulsed Dendritic Cell Immunotherapy for Patients With Brain Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00576537
Recruitment Status : Completed
First Posted : December 19, 2007
Last Update Posted : May 3, 2019
Information provided by (Responsible Party):
John Yu, Cedars-Sinai Medical Center

Brief Summary:
This research is being determine whether vaccinations with your own immune cells called " dendritic cells " can activate your immune system to fight your brain tumor.

Condition or disease Intervention/treatment Phase
Glioblastoma Biological: Dendritic Cell Immunotherapy Phase 2

Detailed Description:

To become eligible for therapy the following criteria must be fulfilled:

  • No age or gender limit
  • Patients with atypical malignant brain tumors.
  • Must have a Karnofsky performance of at least 60%
  • Hematologic studies and chemistry profiles will be within the parameters of the protocol
  • Tumor specimen of adequate size to yield protein concentration, tumor lysate peptide must be generated in sufficient quantity and patient must have no prior sensitivity to the components of the dendritic cell vaccine.
  • Patients are excluded if they have systemic disease, presence of acute infection, known history of autoimmune disorder and pregnancy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase ll Trial of Tumor Lysate-Pulsed Dendritic Cell Immunotherapy for Patients With Atypical or Malignant, Primary or Metastatic Brain Tumors of the Central Nervous System
Study Start Date : March 2001
Actual Primary Completion Date : October 2011
Actual Study Completion Date : October 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Dendritic Cell Immunotherapy
Patients who consent to participate in the study and receive the Dendritic Cell vaccine manufactured from their own tumor cells.
Biological: Dendritic Cell Immunotherapy
Patients will receive four vaccines.
Other Name: Dendritic Cell vaccine

Primary Outcome Measures :
  1. Evaluate the safety/toxicity of subcutaneous injections of autologous dendritic cells [ Time Frame: One year ]
    Cytotoxic T lymphocyte (CTL) precursor frequency

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • No age or gender limit, though minimal weight limitations for apheresis is about 15 - 20 Kg.
  • Both male and female of childbearing age entering the protocol must use a medically accepted form of birth control during the study, will be required to have a negative pregnancy test for female.
  • patients with atypical malignant brain tumor will be eligible.
  • Patients must have a Karnofsky performance score of at least 60%
  • patients may be maintained on glucocorticoid therapy at the lowest possible dose.
  • Baseline hematologic studies and chemistry profiles must meet the criteria.
  • Tumor specimen of adequate size to yield protein concentration in sufficient quantity.
  • Tumor-lysate peptide must be generated in sufficient quantity to pulse the APC's for vaccination.
  • Patient must have no prior sensitivity to the components of the dendritic cell vaccine.
  • Patient must agree to consider an autopsy in the event of death in an attempt to learn more concerning the nature of this treatment and tumor biology.
  • Patient must be capable of signing IRB approved Research Consent and Release of medical Records form.

Exclusion Criteria:

  • Severe pulmonary, cardiac or other systemic disease associated with an unacceptable anesthetic or operative risk.
  • The presence of an acute infection requiring active treatment will be criteria for delay or exclusion.
  • Patients with a known history of an autoimmune disorder.
  • Inability to give informed consent.
  • Pregnancy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00576537

Layout table for location information
United States, California
Cedars Sinai Medical center
Los Angeles, California, United States, 90048
Sponsors and Collaborators
Cedars-Sinai Medical Center
Layout table for investigator information
Principal Investigator: John Yu, M.D. Cedars-Sinai Medical Center
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: John Yu, MD, Cedars-Sinai Medical Center Identifier: NCT00576537    
Other Study ID Numbers: 3368
First Posted: December 19, 2007    Key Record Dates
Last Update Posted: May 3, 2019
Last Verified: April 2019
Keywords provided by John Yu, Cedars-Sinai Medical Center:
New/Recurrent Glioblastoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Immunomodulating Agents
Immunologic Factors
Physiological Effects of Drugs